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Abstract
The aim of this work was to assess the effect of chronic administration of protonated
nanostructured aluminosilicate (NSAS) on the plasma cholesterol levels and development of
atherosclerotic lesions in Apolipoprotein (ApoE) deficient mice fed a high cholesterol and high fat
diet. Apolipoprotein E (ApoE) deficient mice were divided into the following treatment groups:
protonated NSAS 1.4% (w/w), untreated control and 2% (w/w) stigmastanol mixed with high-
cholesterol/high-fat diet. Animals were treated for 12 weeks, blood samples were withdrawn every
4 weeks for determination of plasma cholesterol and triglyceride levels. At the end of the study the
aortic roots were harvested for assessment of atherosclerotic lesions. NSAS at 1.4% (w/w) and
stigmastanol at 2% (w/w) treatment groups showed significant decreases in plasma cholesterol
concentrations at all time points relative to the control animals. The lesion sum area in 1.4% (w/w)
NSAS and 2% (w/w) stigmastanol groups were significantly less from the control animals. In
conclusion, in this study, the effectiveness of chronic administration of protonated NSAS material
in the reduction of plasma cholesterol levels and decrease in development of atherosclerotic
lesions was demonstrated in Apo-E deficient mice model.
Introduction
Elevated plasma cholesterol levels have been associated
with increased risk of atherosclerosis and coronary artery
disease [1]. Although competitive inhibitors of 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase (statins) are the gold standard in the treatment
of hypercholesterolemia, there is a long history of use of
cholesterol absorption inhibitors as an alternative/adju-
vant method of treating hypercholesterolemia [1]. The
main agents are plant sterols, plant stanols and ezetimibe.
However, since these agents are reported to be absorbed
into blood circulation, there is a potential for systemic
adverse effects [2-5]. Potential candidates for non-absorb-
able agents for inhibiting gastrointestinal absorption of
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cholesterol would be the naturally occurring aluminosili-
cates clays (Figure 1) [6]. A calcium montmorillonite clay
has been reported to be safe and effective in reducing of
exposure to aflatoxin by adsorption mechanism in
rodents and humans [7,8]. We have previously reported
that protonated nanoscaled aluminosilicate compound
efficiently inhibited the intestinal absorption of choles-
terol following acute administration in a rat model [[9];
See Additional File 1]. It was unclear, however, what will
be the effect of NSAS in the chronic administration on
plasma cholesterol levels and on development of patho-
physiology of atherosclerosis [10]. Thus, the current study
was designed to elucidate the effect of chronic administra-
tion of protonated form of NSAS to Apolipoprotein-E
(Apo-E) deficient mice on plasma cholesterol concentra-
tions and formation of aortic atherosclerotic lesions.
Methods
Mice, C57B1/6 B6.129P2-ApoE™1UNC, 4 week old, with
homozygous deletion of the ApoE gene (apolipoprotein E
knock-out) were purchased from Jackson Laboratories,
USA. The Apo-E deficient mice model has been used
extensively, since these mice develop severe hypercholes-
terolemia and atherosclerotic lesions similar to those
observed in humans [10,11].
The protonated NSAS material was prepared as previously
reported [[9], See Additional File 1]. Briefly, the crude
NSAS was dried to 10% moisture content and the particle
size was reduced by a passing through a 200 mesh (74
μm) screen. The base NSAS was then purified by a previ-
ously reported method [12] and mixed with deionized
water using a blender at 11,500 rpm for 5 min. As a result
of the purification process essentially all of the exchange-
able surface cations were replaced by sodium ions.
Sodium NSAS sample was pumped through two lab-scale
ion-exchange columns filled with hydrogen-loaded resin
exchange beads to protonate the montmorillonite.
All animals used in this study were cared for in accordance
with the principles promulgated by the Canadian Council
in Animal Care and the University of British Columbia.
The research adhered to the "Principles of Laboratory Ani-
mal Care" (NIH publication #85-23, revised in 1985).
The Apo-E deficient mice (Jackson Laboratories, USA)
were divided into the following treatment groups: proto-
nated NSAS 1.4% w/w, untreated control and 2% w/w
stigmastanol. All animals received high-cholesterol/high-
fat diet (45 kcal% fat) (Research Diets Inc., USA) for the
duration of the study. The tested active compounds were
incorporated into the diet. All animals were treated for 12
weeks. Blood samples were withdrawn from saphenous
vein every 4 weeks and at the end of the study for determi-
nation of total plasma cholesterol and triglyceride levels.
Schematic presentation of montmorillonite structure Figure 1
Schematic presentation of montmorillonite struc-
ture. Montmorillonite is a layered silicate with the property 
of adsorbing organic substances on its external surfaces or 
within its interlaminar space. The hydration of the clay 
induces swelling, which is mostly attributed to the increase in 
d (or c) dimension.Lipids in Health and Disease 2009, 8:30 http://www.lipidworld.com/content/8/1/30
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At the end of the study the animals were sacrificed and
aortic arch was harvested for histopathology assessment
of atherosclerotic lesions in control animals and in groups
that showed statistically significant differences in their
plasma lipid profile relatively to the control group. Tissue
surrounding the aorta including all fat were trimmed, and
frozen in liquid nitrogen. The aorta was cut in 3 consecu-
tive slices (10 μmol/L) 5 mm above the aortic root. Slides
were stained with Oil-Red-O, Movat's Pentachrome and
Hematoxylin-eosin. An independent pathologist, blinded
to the treatment groups scored the lesion formation based
on cumulative atherosclerotic exposure area (sum area).
Statistical analyses were performed using one-way
ANOVA followed by Dunnett multiple comparisons test.
Results were expressed as mean +/- SEM, p < 0.05 indi-
cated a significant difference between groups.
Results and discussion
All animals based on physical appearance did not appear
to have any deleterious effects from administration of
NSAS at 1.4% w/w or stigmastanol at 2% w/w. The activity
and behaviour of the animals were similar between all
groups and consistent with the ApoE deficient phenotype.
The baseline of the body weight was 19 g (average) and
after 12 weeks was 33.2 (average). As a result of similar
food and water consumption (data not shown) during all
period of study, the body weight increased by the same
amount over the experimental period in all groups (treat-
ment and control) (Figure 2). The average food intake for
all treatment and control groups throughout the duration
of study was 3.14 g per day (Figure 3).
The total plasma cholesterol concentrations through
duration of the study in different treatment groups are
shown in Figure 4. The treatment by protonated NSAS at
1.4% w/w and stigmastanol at 2% w/w resulted in a sig-
nificant decrease in plasma cholesterol levels at 4, 8 and
12 weeks of the study compared to untreated controls.
This cumulative reduction in plasma cholesterol levels
over the duration of the study is reflected by a statistically
significant difference in histopahotogically evaluated total
area covered by atherosclerotic lesion in the 1.4% w/w
NSAS and 2% w/w stigmastanol treatment groups com-
pared to untreated controls (Figure 5). The change in
plasma triglyceride levels through duration of the study in
different treatment groups is shown in Figure 6. There are
no statistically significant differences in total triglyceride
levels as well as in change in triglyceride levels from the
baseline between all treatment groups, at all time points,
relatively to the control animals. This observation, in
addition to the fact that there were no changes in body
weight (Figure 2) and food intake (Figure 3) throughout
the study indicates that it is unlikely that protonated NSAS
compound affects significantly the intestinal absorption
of triglyceride which is the main component of lipids in
the diet. When the food intake in figure 3 is plotted as
cumulative intake over time for each group no statistically
significant differences are observed (data not shown).
Thus the effect we observe in Figure 4 (plasma cholesterol
levels) and Figure 5 (atherosclerotic lesion area) is due to
the effect of the compounds.
In conclusion, in this study we have demonstrated the
effect of protonated NSAS material on reducing plasma
Body weight (Mean +/- SEM) from the beginning of the treat- ment (week 0) in the Apo-E deficient mice treated with 1.4%  w/w (n = 8) of protonated NSAS, 2% w/w stigmastanol (n =  7) vs. untreated control (n = 8) Figure 2
Body weight (Mean +/- SEM) from the beginning of 
the treatment (week 0) in the Apo-E deficient mice 
treated with 1.4% w/w (n = 8) of protonated NSAS, 
2% w/w stigmastanol (n = 7) vs. untreated control (n 
= 8). No statistically significant differences between treat-
ment and untreated control groups were observed.
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Control 1.4% protonated NSAS 2% Stigmastanol
Weekly food in-take (Mean +/- SEM) from the beginning of  the treatment (week 0) in the Apo-E deficient mice treated  with 1.4% w/w (n = 8) of protonated NSAS, 2% w/w stigmas- tanol (n = 7) vs. untreated control (n = 8) Figure 3
Weekly food in-take (Mean +/- SEM) from the begin-
ning of the treatment (week 0) in the Apo-E deficient 
mice treated with 1.4% w/w (n = 8) of protonated 
NSAS, 2% w/w stigmastanol (n = 7) vs. untreated 
control (n = 8). No statistically significant differences 
between treatment and untreated control groups were 
observed. SEM were not shown in this figure.
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cholesterol concentrations and the development of
atherosclerotic lesions in Apo-E deficient mice model fol-
lowing chronic administration. The chronic administra-
tion of protonated NSAS material on cholesterol
absorption seems not to affect the intestinal absorption of
triglyceride, as demonstrated by absence of changes in
plasma triglyceride concentrations and lack of differences
in body weight and food intake. The shown significant
effect of supplementation of high fat/high cholesterol diet
with protonated NSAS material on the formation of
atherosclerotic lesions is particularly important, since the
final aim of cholesterol-lowering treatment is reduction of
the development of atherosclerosis. Although the effect of
protonated NSAS material on inhibition of cholesterol
absorption following acute administration was demon-
strated previously [[9], See Additional File 1], and the ben-
eficial effect of chronic administration on plasma
cholesterol levels and atherosclerotic lesions formation in
Apo-E deficient mice was demonstrated in this study, the
mechanism of cholesterol absorption inhibition is still
not completely clear. In addition, a dose-response study
with protonated NSAS would be required to confirm its
activity. Future mechanistic studies aimed to elucidate the
mechanism(s) by which the protonated form of NSAS
material inhibits the intestinal absorption of cholesterol
will be needed.
Abbreviations
NSAS: nanostructured aluminosilicate; ApoE: apolipopro-
tein E; TC: total cholesterol; TG: triglyceride.
Total plasma cholesterol concentrations (Mean +/- SEM)  from the beginning of the treatment (week 0) to the end of  treatment (week 12) in the Apo-E deficient mice treated with  1.4% w/w (n = 8) of protonated NSAS, 2% w/w stigmastanol  (n = 7) vs. untreated control (n = 8) Figure 4
Total plasma cholesterol concentrations (Mean +/- 
SEM) from the beginning of the treatment (week 0) 
to the end of treatment (week 12) in the Apo-E defi-
cient mice treated with 1.4% w/w (n = 8) of proto-
nated NSAS, 2% w/w stigmastanol (n = 7) vs. 
untreated control (n = 8). Statistically significant differ-
ences for both 1.4% w/w protonated NSAS and 2% w/w stig-
mastanol at 4, 8 and 12 weeks compared to untreated 
controls (*p < 0.05 vs. untreated controls and **p < 0.01 vs. 
untreated controls) were observed; one-way ANOVA fol-
lowed by Dunnett multiple comparisons test
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Total area covered by atherosclerotic lesion (Mean +/- SEM)  in ApoE-deficient mice treated with 1.4% w/w (n = 8) of pro- tonated NSAS, 2% w/w stigmastanol (n = 7) vs. untreated  control (n = 8) Figure 5
Total area covered by atherosclerotic lesion (Mean +/
- SEM) in ApoE-deficient mice treated with 1.4% w/w 
(n = 8) of protonated NSAS, 2% w/w stigmastanol (n 
= 7) vs. untreated control (n = 8). Statistically significant 
differences for both 1.4% protonated NSAS and 2% w/w stig-
mastanol compared to untreated controls (*p < 0.05 vs. 
untreated controls) were observed; one-way ANOVA fol-
lowed by Dunnett multiple comparisons test.
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Total plasma triglyceride concentrations (Mean +/- SEM)  from the beginning of the treatment (week 0) to the end of  treatment (week 12) in the Apo-E deficient mice treated with  1.4% w/w (n = 8) of protonated NSAS, 2% w/w stigmastanol  (n = 7) vs. untreated control (n = 8) Figure 6
Total plasma triglyceride concentrations (Mean +/- 
SEM) from the beginning of the treatment (week 0) 
to the end of treatment (week 12) in the Apo-E defi-
cient mice treated with 1.4% w/w (n = 8) of proto-
nated NSAS, 2% w/w stigmastanol (n = 7) vs. 
untreated control (n = 8). No statistically significant dif-
ferences between treatment and untreated control groups 
were observed.
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